Cargando…
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
AIMS: To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs) cause atherosclerotic cardiovascular disease (ASCVD). METHODS AND RESULTS: We assessed whether the association between LDL and ASCVD fulfils the criteria for causality by evaluating the totality of evidence from...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837225/ https://www.ncbi.nlm.nih.gov/pubmed/28444290 http://dx.doi.org/10.1093/eurheartj/ehx144 |
_version_ | 1783304080169369600 |
---|---|
author | Ference, Brian A. Ginsberg, Henry N. Graham, Ian Ray, Kausik K. Packard, Chris J. Bruckert, Eric Hegele, Robert A. Krauss, Ronald M. Raal, Frederick J. Schunkert, Heribert Watts, Gerald F. Borén, Jan Fazio, Sergio Horton, Jay D. Masana, Luis Nicholls, Stephen J. Nordestgaard, Børge G. van de Sluis, Bart Taskinen, Marja-Riitta Tokgözoğlu, Lale Landmesser, Ulf Laufs, Ulrich Wiklund, Olov Stock, Jane K. Chapman, M. John Catapano, Alberico L. |
author_facet | Ference, Brian A. Ginsberg, Henry N. Graham, Ian Ray, Kausik K. Packard, Chris J. Bruckert, Eric Hegele, Robert A. Krauss, Ronald M. Raal, Frederick J. Schunkert, Heribert Watts, Gerald F. Borén, Jan Fazio, Sergio Horton, Jay D. Masana, Luis Nicholls, Stephen J. Nordestgaard, Børge G. van de Sluis, Bart Taskinen, Marja-Riitta Tokgözoğlu, Lale Landmesser, Ulf Laufs, Ulrich Wiklund, Olov Stock, Jane K. Chapman, M. John Catapano, Alberico L. |
author_sort | Ference, Brian A. |
collection | PubMed |
description | AIMS: To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs) cause atherosclerotic cardiovascular disease (ASCVD). METHODS AND RESULTS: We assessed whether the association between LDL and ASCVD fulfils the criteria for causality by evaluating the totality of evidence from genetic studies, prospective epidemiologic cohort studies, Mendelian randomization studies, and randomized trials of LDL-lowering therapies. In clinical studies, plasma LDL burden is usually estimated by determination of plasma LDL cholesterol level (LDL-C). Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD, whereas rare variants leading to lower LDL-C are associated with a correspondingly lower risk of ASCVD. Separate meta-analyses of over 200 prospective cohort studies, Mendelian randomization studies, and randomized trials including more than 2 million participants with over 20 million person-years of follow-up and over 150 000 cardiovascular events demonstrate a remarkably consistent dose-dependent log-linear association between the absolute magnitude of exposure of the vasculature to LDL-C and the risk of ASCVD; and this effect appears to increase with increasing duration of exposure to LDL-C. Both the naturally randomized genetic studies and the randomized intervention trials consistently demonstrate that any mechanism of lowering plasma LDL particle concentration should reduce the risk of ASCVD events proportional to the absolute reduction in LDL-C and the cumulative duration of exposure to lower LDL-C, provided that the achieved reduction in LDL-C is concordant with the reduction in LDL particle number and that there are no competing deleterious off-target effects. CONCLUSION: Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD. |
format | Online Article Text |
id | pubmed-5837225 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-58372252018-03-09 Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel Ference, Brian A. Ginsberg, Henry N. Graham, Ian Ray, Kausik K. Packard, Chris J. Bruckert, Eric Hegele, Robert A. Krauss, Ronald M. Raal, Frederick J. Schunkert, Heribert Watts, Gerald F. Borén, Jan Fazio, Sergio Horton, Jay D. Masana, Luis Nicholls, Stephen J. Nordestgaard, Børge G. van de Sluis, Bart Taskinen, Marja-Riitta Tokgözoğlu, Lale Landmesser, Ulf Laufs, Ulrich Wiklund, Olov Stock, Jane K. Chapman, M. John Catapano, Alberico L. Eur Heart J Current Opinion AIMS: To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs) cause atherosclerotic cardiovascular disease (ASCVD). METHODS AND RESULTS: We assessed whether the association between LDL and ASCVD fulfils the criteria for causality by evaluating the totality of evidence from genetic studies, prospective epidemiologic cohort studies, Mendelian randomization studies, and randomized trials of LDL-lowering therapies. In clinical studies, plasma LDL burden is usually estimated by determination of plasma LDL cholesterol level (LDL-C). Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD, whereas rare variants leading to lower LDL-C are associated with a correspondingly lower risk of ASCVD. Separate meta-analyses of over 200 prospective cohort studies, Mendelian randomization studies, and randomized trials including more than 2 million participants with over 20 million person-years of follow-up and over 150 000 cardiovascular events demonstrate a remarkably consistent dose-dependent log-linear association between the absolute magnitude of exposure of the vasculature to LDL-C and the risk of ASCVD; and this effect appears to increase with increasing duration of exposure to LDL-C. Both the naturally randomized genetic studies and the randomized intervention trials consistently demonstrate that any mechanism of lowering plasma LDL particle concentration should reduce the risk of ASCVD events proportional to the absolute reduction in LDL-C and the cumulative duration of exposure to lower LDL-C, provided that the achieved reduction in LDL-C is concordant with the reduction in LDL particle number and that there are no competing deleterious off-target effects. CONCLUSION: Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD. Oxford University Press 2017-08-21 2017-04-24 /pmc/articles/PMC5837225/ /pubmed/28444290 http://dx.doi.org/10.1093/eurheartj/ehx144 Text en © The Author 2017. Published on behalf of the European Society of Cardiology http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Current Opinion Ference, Brian A. Ginsberg, Henry N. Graham, Ian Ray, Kausik K. Packard, Chris J. Bruckert, Eric Hegele, Robert A. Krauss, Ronald M. Raal, Frederick J. Schunkert, Heribert Watts, Gerald F. Borén, Jan Fazio, Sergio Horton, Jay D. Masana, Luis Nicholls, Stephen J. Nordestgaard, Børge G. van de Sluis, Bart Taskinen, Marja-Riitta Tokgözoğlu, Lale Landmesser, Ulf Laufs, Ulrich Wiklund, Olov Stock, Jane K. Chapman, M. John Catapano, Alberico L. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel |
title | Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel |
title_full | Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel |
title_fullStr | Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel |
title_full_unstemmed | Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel |
title_short | Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel |
title_sort | low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. evidence from genetic, epidemiologic, and clinical studies. a consensus statement from the european atherosclerosis society consensus panel |
topic | Current Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837225/ https://www.ncbi.nlm.nih.gov/pubmed/28444290 http://dx.doi.org/10.1093/eurheartj/ehx144 |
work_keys_str_mv | AT ferencebriana lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT ginsberghenryn lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT grahamian lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT raykausikk lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT packardchrisj lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT bruckerteric lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT hegeleroberta lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT kraussronaldm lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT raalfrederickj lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT schunkertheribert lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT wattsgeraldf lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT borenjan lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT faziosergio lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT hortonjayd lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT masanaluis lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT nichollsstephenj lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT nordestgaardbørgeg lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT vandesluisbart lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT taskinenmarjariitta lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT tokgozoglulale lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT landmesserulf lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT laufsulrich lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT wiklundolov lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT stockjanek lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT chapmanmjohn lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel AT catapanoalbericol lowdensitylipoproteinscauseatheroscleroticcardiovasculardisease1evidencefromgeneticepidemiologicandclinicalstudiesaconsensusstatementfromtheeuropeanatherosclerosissocietyconsensuspanel |